AP Biosciences
AP Biosciences is a Taiwan-based biotechnology company running 2 late-stage cancer trials of AP203, AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion) in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer.
Overview
AP Biosciences, based in Taipei, Taiwan, is a biotechnology company listed as TPEx: 6945. AP Biosciences develops biopharmaceuticals through mechanism-based drug design, focusing on tumour-associated antigens and disease-specific targets. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AP203, AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion) in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer. The largest, NCT05473156 (A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumours, and Expansion to Selected Malignancies), plans to enrol 168 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyEpicentRx
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyVyriad
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAveta Biomics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyQBiotics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.